South Korean-based drug manufacturer, Celltrion, has granted exclusive distribution rights of its trastuzumab biosimilar, Herzuma, to the Mundipharma global network of independent associated companies.
South Korean-based drug manufacturer, Celltrion, has granted exclusive distribution rights of its trastuzumab biosimilar, Herzuma, to the Mundipharma global network of independent associated companies. The rights apply to 7 European nations.
“We are pleased to be partnering once again with Mundipharma on the commercialization of our trastuzumab biosimilar,” said Man Hoon Kim, president and chief executive of Celltrion in a statement. “They have a proven track record of launching biosimilars in Europe, working effectively across multiple healthcare systems and demonstrating local in-market expertise. This alliance enables us to continue to pursue our commitment to delivering effective and affordable medicines which benefit healthcare systems, healthcare professionals and patients.”
Richard Trollope, commercial head of oncology and biosimilars at Mundipharma, added, “Celltrion’s decision to entrust us with a third biosimilar from their portfolio is testament to the insight and experience we have developed from successfully launching [2] previous monoclonal antibody biosimilars. With infliximab [Remsima], we achieved market-leading status in the majority of our markets, and we are already seeing strong market uptake with our newest biosimilar medicine, rituximab [Truxima], across those markets where we have distribution rights.”
The trastuzumab biosimilar was granted marketing authorization on February 9 of this year after receiving a positive opinion and recommendation for approval by the European Medicines Agnecy’s and the Committee for Medicinal Products for Human Use in December 2017. The biosimilar is approved for treatment of HER2-positive early breast cancer in the neo-adjuvant and adjuvant setting, metastatic breast cancer, and metastatic gastric cancer in adults.
Herzuma will not be the only trastuzumab biosimilar on the market in Europe. Samsung Bioepis, another Republic of Korea drug maker, has also received marketing authorization for its own trastuzumab biosimilar. The biosimilar is being commercialized by Merck and will be marketed in Europe as Ontruzant. Both products will compete with the reference trastuzumab, Herceptin, which generated global sales of $7.4 billion for developer Roche in 2017.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.